Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient ...

Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...

Radiotherapeutics were a major topic at ASCO this year, as more and more studies progress on a variety of targets, isotopes, ...

Takeda presented data across a range of therapeutics and indications at ASCO 2026, including on investigational drugs like ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for ...

San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds ...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. The funding aims to improve clinical trials, manufacturing, and HTA across the four nations of the UK. The scheme ...

Armed with new clinical data, Novartis is planning to talk to global regulators about possible filings for delpacibart braxlosiran (del-brax), which could become the first disease-modifying treatment ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...

Still from Lilly's Don't Sleep on OSA TV campaign featuring Shaquille O'Neal. Eli Lilly has enlisted the aid of US basketball legend Shaquille O'Neal to publicise a new campaign to raise awareness of ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...